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Background: Lennox–Gastaut syndrome (LGS) is a severe childhood epileptic syn-
drome with high pharmacoresistance. The treatment outcomes are still unsatisfied. Our 
previous study of cathodal transcranial direct current stimulation (tDCS) in children with 
focal epilepsy showed significant reduction in epileptiform discharges. We hypothesized 
that cathodal tDCS when applied over the primary motor cortex (M1) combined with 
pharmacologic treatment will be more effective for reducing seizure frequency in patients 
with LGS than pharmacologic treatment alone.
Materials and methods: Study participants were randomized to receive either (1) 
pharmacologic treatment with five consecutive days of 2 mA cathodal tDCS over M1 for 
20 min or (2) pharmacologic treatment plus sham tDCS. Measures of seizure frequency 
and epileptic discharges were performed before treatment and again immediately 
post-treatment and 1-, 2-, 3-, and 4-week follow-up.
result: Twenty-two patients with LGS were enrolled. Participants assigned to the active 
tDCS condition reported significantly more pre- to post-treatment reductions in seizure 
frequency and epileptic discharges that were sustained for 3 weeks after treatment.
Conclusion: Five consecutive days of cathodal tDCS over M1 combined with pharma-
cologic treatment appears to reduce seizure frequency and epileptic discharges. Further 
studies of the potential mechanisms of tDCS in the LGS are warranted.
Trial registration: ClinicalTrials.gov, NCT02731300 (https://register.clinicaltrials.gov).
Keywords: transcranial direct current stimulation, cathodal stimulation, childhood pharmacoresistant epilepsy, 
lennox–Gastaut syndrome
inTrODUCTiOn
Lennox–Gastaut syndrome (LGS) is a severe childhood epileptic syndrome that is characterized 
by multiple types of seizures including a nucleus of brief tonic, atonic seizures, atypical absences, 
and less characteristically, myoclonic attacks associated with an interictal electroencephalography 
(EEG) pattern of diffuse, slow spike–wave complexes <2.5  Hz (1). The prevalence of LGS was 
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approximately 3–10.7% of all cases of childhood epilepsies (2, 
3), and the incidence reported in Finland was 2/100,000 among 
children aged 1–14  years (4). Almost all LGS are mentally 
retarded (5, 6). This syndrome is highly pharmacoresistant 
(7) and required non-pharmacologic interventions such as 
ketogenic diet, vagus nerve stimulation, and epilepsy surgery 
including callosotomy and focal curative resection that takes 
risk and ineffective (8).
Transcranial direct current stimulation (tDCS) is a painless 
and safe method for focal brain stimulation (9). tDCS is based on 
decade-old observations that neuronal firing can be modulated 
by low amplitude electrical direct current (10). Even though 
the electrical current used in tDCS is low, it is large enough to 
decrease the threshold needed to generate hyperpolarization in 
neurons immediately below the cathodal (negative) electrode. 
Thus, it is thought to modulate cortical excitability by altering 
cell membrane potential. Although the precise mechanisms that 
underlie tDCS are not yet completely understood, the overall 
effect on the human cortex is reliable, such that anodal tDCS 
facilitates cortical activity and cathodal tDCS depresses cortical 
activity (11).
Transcranial direct current stimulation units are light weight 
and inexpensive. It is presently under investigation for epilepsy 
treatment, where excess cortical excitability is a prominent 
feature and neuronal inhibition from cathodal tDCS may be 
beneficial. For treatment of seizures, tDCS may offer a practi-
cal therapeutic option with the benefit of easy, rapid, and focal 
application in the setting of acute seizure or other form of brain 
injury (12, 13).
A previous study has suggested that cortical excitability 
observed in LGS was decreased when compared to patients 
with chronic refractory focal epilepsy and healthy non-epilepsy 
controls (14). Recently, a number of studies have suggested that 
cathodal tDCS may be useful in suppressing seizures. A previ-
ous study of tDCS in a focal epilepsy rodent model showed a 
significant elevation of the seizure threshold (15) and decreased 
convulsions following pilocarpine-induced status epilepticus in 
rats (16). A clinical trial of cathodal tDCS in 19 adult patients 
with refractory epilepsy showed the effective suppression of 
epileptiform discharges on EEG, but only a trend toward clinical 
improvement (17). In addition, our previous study of a single 
cathodal tDCS in 36 children with refractory focal epilepsy also 
showed significant reductions in epileptic discharge immediately 
and both 24 and 48 h after tDCS. The seizure frequency was also 
decreased for 4 weeks after treatment (18).
As mentioned previously, no research has yet examined the 
effects of cathodal tDCS for LGS. However, given that LGS may 
share some pathophysiology with refractory focal epilepsy that 
could be response to anti-epileptic effect, specifically, the action 
on, epileptic neurons and synchronization (19, 20). It is reason-
able to examine the potential effects of cathodal tDCS on LGS. We 
hypothesized that five consecutive days of cathodal tDCS would 
result in significantly more pre- to post-treatment decreases in 
seizure frequency than 5 days of sham tDCS stimulation, and that 
the differences in seizure frequency would maintain for at least 
4 weeks post-treatment. Therefore, the objective of our study was 
to test the efficacy of tDCS in the pediatric LGS population.
MaTErialS anD METHODS
Participant recruitment and informed 
Consent
Study participants were recruited via advertisement at the 
pediatric outpatient department, Srinagarind hospital, Faculty of 
Medicine, Khon Kaen University, Thailand. The study procedures 
were described to any eligible patients who expressed an interest 
in participating in the study by a pediatric neurologist. Criteria 
for LGS were defined according to the triad of (1) polymorphic 
intractable seizures that are mainly tonic, atonic, and atypical 
absence seizures, (2) cognitive and behavioral abnormalities, 
(3) EEG with paroxysms of fast activity and slow (<2.5  Hz) 
generalized spike-wave discharges (GSWD) (21). The diagnosis 
was confirmed by a pediatric neurologist using the thoroughly 
history taking, physical examination, EEG, and brain MRI. Study 
inclusion criteria included (a) diagnosis of LGS; (b) failure of 
more than two first-line AEDs to control seizures; (c) average 
seizure frequency of more than one per month for 18 months and 
no more than three consecutive seizure-free months during that 
interval; (d) age between 6 and 15 years. The exclusion criteria 
were (a) drug addiction, pregnancy, skull defect, and other serious 
neurological diseases; and (b) change in dosage of antiepileptic 
drugs or use of herbal remedies and other alternative therapies.
All patients’ guardians gave their written informed consent. 
The study conformed to the declaration of Helsinki and was 
approved by the Ethics Committee of Khon Kaen University 
(Identifier number: HE 521232).
Experimental Design
The current study was a randomized, double-blind controlled 
trial performed over a total of 6 weeks consisting of (1) a 1-week 
period of observation to assess the baseline seizure frequency, 
(2) a five consecutive days of 2 mA cathodal tDCS for 30 min, 
and (3) 4  weeks of follow-up. Just before the treatment phase, 
study participants were randomized in a 2:1 ratio in blocks of four 
randomizations to receive either (a) pharmacologic treatment 
plus active tDCS stimulation or (b) pharmacologic treatment plus 
sham tDCS stimulation for 5 days. Participants were asked to con-
tinue their routine anti-epileptic medication regimen throughout 
the duration of the 6-week trial.
Pharmacologic Treatment
Since there is a considerable degree of heterogeneity with 
LGS, individualized approaches are necessary. We first use the 
antiepileptic drugs that currently approved by the Food and 
Drug Administration and available in our institute: lamotrigine, 
topiramate, clobazam, and clonazepam depended on seizure 
types. We gave lamotrigine 1–20 mg/kg/day with slowly titration 
for tonic, tonic–clonic, atypical absences, and atonic seizures. 
Clobazam 0.25–3.5 mg/kg/day was added in the cases that refrac-
tory to lamotrigine and in the patients with myoclonic seizures. 
We used clonazepam 0.04–0.2 mg/kg/day instead of clobazam in 
some cases when clobazam was not available. We used topiramate 
1–10 mg/kg/day in the patients who refractory to lamotrigine and 
clobazam. In some cases, that refractory to the aforementioned 
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antiepileptic drugs, we gave zonisamide 1–20  mg/kg/day, 
levetiracetam 10–80 mg/kg/day, and nitrazepam 0.1–0.8 mg/kg/
day (8).
Randomization and Blinding
Prior to the treatment phase, study participants were randomized 
in a 2:1 ratio in blocks of four randomizations (by OT) to receive 
either (1) active tDCS stimulation or (2) sham tDCS stimulation. 
Participants were asked to continue their routine medication 
regimen throughout the trial. The staff who generated the random 
allocation sequence, enrolled participants, and assigned partici-
pants to interventions were not involved in any assessments. After 
assignment to the intervention groups, the pediatric neurologist 
who carried out the seizure assessments (Narong Auvichayapat) 
was blind to treatment condition. Because the study participants 
were also blind to treatment condition, this is a double-blind 
study.
Active and Sham Transcranial Direct Current 
Stimulation
Transcranial direct current stimulation was applied via water-
soaked pair of surface sponge electrodes (35 cm2) and delivered 
through battery-driven power supply. The constant current 
stimulator had a maximum output of 10  mA (Soterixmedical, 
Model 1224-B, New York, NY, USA). The stimulation site over 
the left M1, located based on the international electroencepha-
lography (EEG) 10/20 electrode placement system. The reference 
electrode was placed over the right shoulder area.
The tDCS device was designed to allow sham stimulation 
by placing the control switch in front of the instrument, which 
was easily covered by an opaque adhesive during stimulation. 
Therefore, the patients or their gradients could not know whether 
active or sham stimulation. The power lit up indicator was also 
on the front of the machine during the time of intervention both 
in active and sham stimulations. However, in sham stimulation, 
the current was discontinued after 30 s, while the power indicator 
remained on (18).
Measures
Number of Seizures
Since Lennox–Gastaut Syndrome composed of many seizure 
types. All seizures were classified according to the International 
League Against Epilepsy Revised Classification of Seizures (22). 
The patients were monitored by video-EEG in order to classify the 
types and frequencies of seizures, and all of the caregivers were 
taught how to count and classify seizures on the basis of observa-
tions and video recordings. The caregivers were also taught the 
rules for diary recording prior to the baseline period. All of the 
caregivers were blinded to both treatment and sham group. In 
case of the patient who had more than one caregiver, we suggested 
them to refer the daily diary to the person who cared the patient 
in time.
Number of seizures was the primary outcome variable, 
and was assessed by using a daily diary. For the baseline (pre-
treatment) assessment, the caregivers were asked to record the 
number of seizures every day for 7  days during the baseline 
period on a daily diary. These 7 days, numbers of seizures were 
averaged into a single rate per day of baseline average seizure 
frequency. During the five consecutive days of treatment, the 
caregivers were asked to record the daily children seizure 
frequency. Finally, daily 24-h recording were administered for 
4 weeks following treatment. 1-, 2-, 3-, and 4-week composite 
number of seizures were computed as an average of the daily 
number of seizures for each epoch (i.e., the 1-week follow-up 
average number of seizures = average of seven daily number of 
seizures the first week after treatment).
Epileptic Discharges
Epileptic discharges, the secondary outcome variable of this 
study, were recorded by a trained staff. EEG was acquired from 
all patients using a 32-channel, international 10–20 system of 
electrode placement (Neuvo, Compumedics, Australia with 
PerFusion EEG software). EEG was collected for 30  min in 
the awake state only. EEG was recorded as a single session at 
baseline, immediately, 1-, 2-, 3-, and 4-week follow-up. EEG 
data were analyzed by visual inspection. The numbers of epi-
leptic discharges in the 30-min recording were assessed by a 
practicing pediatric neurologist and clinical neurophysiologist 
(Narong Auvichayapat), who was blinded to the treatment con-
dition. The EEGs that included as abnormal EEGs in LGS are 
slow spike–wave complexes at <3 Hz that occur during wake-
fulness. The complexes consist of a spike (duration <70  ms) 
or a sharp wave (70–200 ms), followed first by a positive deep 
trough and then a negative wave (350–400  ms). Paroxysmal 
fast rhythms (10–20  Hz) occur mainly during non-rapid eye 
movement sleep (23). One slow spike–wave complex or one 
episode of paroxysmal fast rhythms were counted as one epi-
leptic discharge.
Vital Signs and Oxygen Saturation Monitoring
All patients were closely observed by physicians during and post-
treatment. Oxygen saturation and vital signs were monitored 
for 30 min before, during, and 30 min after the treatment. Pulse 
rate was measured by automatic sphygmomanometer (Ua-767 
Plus, UK) in the supine position. Blood pressure (millimeter 
of mercury) was measured by automatic sphygmomanometer 
(Ua-767 Plus, UK) in the supine position with a pediatric-size 
cuff wrapped around the right upper arm. Body temperature was 
measured by an axillary electronic thermometer. Respiratory rate 
was measured by counting chest risings for 60 s. Pulse oximeter 
was placed on the left index finger to monitor oxygen saturation 
throughout the procedure.
Adverse Events
Adverse events as well as other signs and symptoms were reported 
by patients’ guardians every day after treatment. Theses self-
recordings terminated at 4 weeks after stimulation.
Statistical analysis
We first computed means and SDs of the demographic and 
outcome variables for descriptive purposes. Next, we compared 
the two treatment conditions (active tDCS vs. sham tDCS) on all 
TaBlE 1 | Demographic data and baseline characteristics (n = 22).
Cathodal tDCS Sham
No. of subjects 15 7
Sex (males/females) 9/6 5/2
Age
 Mean ± SD 6.67 ± 1.54 6.29 ± 1.98
 Range (years) 4–9 3–9
Etiologies of epilepsies
 Idiopathic 6 2
 Infantile spasms 1 1
 Neonatal hypoglycemia 4 3
 Preterm with severe birth asphyxia 2 0
 Preterm with history of 
 intracerebral hemorrhage
2 1
Baseline seizure frequency per day 
(mean ± SD)
80.67 ± 54.43 93.43 ± 59.94
Baseline epileptic discharges per 
30 min (mean ± SD)
640.13 ± 263.30 800.86 ± 374.62
Age at onset of seizures (years) 2.32 ± 2.39 1.58 ± 1.70
Number of antiepileptic drugs used
 3 9 3
 4 4 2
 5 2 2
FiGUrE 1 | image of a single adverse event. Three points of superficial 
skin burn under the reference electrode in active tDCS group, which resolved 
within 2 days.
FiGUrE 2 | Effect of tDCS on seizure frequency. Data are presented as 
mean ± SD of number seizure frequency/day at baseline, treatment period 
(day 1–day 5), and various time points after treatment: 1, 2, 3, and 4 weeks. 
*p = 0.004, **p = 0.002, and ***p < 0.001 as compared to sham tDCS 
condition.
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baseline outcome measures to ensure baseline equivalence using 
t-tests. Results are presented as means and SD. Both the primary 
(seizure frequency) and exploratory (epileptic discharges) 
hypotheses were tested using repeated measures analysis of 
variance (ANOVA) followed by LSD to help understanding any 
significant effects found. To describe the clinical meaningfulness 
of any changes, we computed the percent reduction of number of 
seizures and epileptic discharges in each condition from pre- to 
post-treatment and from pre-treatment to 4-week follow-up. For 
all analyses, p values of <0.05 were considered statistically sig-
nificant. Analyses were completed using STATA software, version 
10.0 (StataCorp, College Station, TX, USA).
rESUlT
The demographic data and baseline patient characteristics 
are described in Table 1. A total of 22 patients with LGS were 
enrolled between August 2010 and December 2013 (Table 1). All 
patients completed the entire protocol and tolerated the tDCS 
well, without serious adverse events. Only one patient had three 
points of 1 mm superficial skin burn under the reference elec-
trode at the day 5 of the treatment period (Figure 1). However, 
the lesion spontaneously resolved in 2 days without scar lesion, 
no other serious side effect was observed.
Clinical Seizure reduction after tDCS
The repeated-measures ANOVA using the number of seizures as 
the dependent variable revealed significant main effects for group 
[F (1, 20) = 63.384; p < 0.001], time [F (9, 20) = 9.813; p < 0.001], 
and group × time interaction [F (9, 20) = 10.023; p < 0.001].
Post hoc analysis showed that the seizure frequency was sig-
nificantly decrease in the tDCS group, relative to the sham tDCS 
group during the treatment period, at day 1 (p = 0.004), day 2 
(p < 0.001), day 3 (p < 0.001), day 4 (p < 0.001), day 5 (p < 0.001). 
In addition, we also found significant decrease in seizure frequency 
at immediately (p < 0.001), 1 week (p < 0.001), 2 week (p < 0.001), 
3 week (p < 0.001), and 4 week (p = 0.002) (Figure 2).
In the active tDCS group, the baseline for seizure frequency 
was 80.67 ±  54.43/day. At the treatment period; decreased to 
37.60 ± 25.96/day (53.39% reduction), 20.60 ± 13.71/day (74.46% 
reduction), 5.87 ± 7.31/day (92.72% reduction), 1.73 ± 4.18/day 
(97.85% reduction), and 0.133 ±  0.52/day (99.84% reduction) 
after the 1, 2, 3, 4, and 5 days of treatment.
After the treatment, the seizure frequency was 8.27 ± 24.23/
day (89.75% reduction), 15.20 ± 14.26/day (81.16% reduction), 
TaBlE 2 | The numbers of individual seizure types and percentage of seizure reduction.
Seizure type active tDCS Sham tDCS p Value
n Mean (SD) % Seizure  
reduction
n Mean (SD) % Seizure  
reduction
Tonic seizures
Baseline frequency 9 21.27 (21.67) 5 25.71 (22.63) 0.663
Day 1 8 9.40 (12.73) 55.81 5 24.00 (23.61) 6.65 0.071
Day 2 7 5.00 (7.11) 76.49 5 26.57 (22.98) −3.35 0.003**
Day 3 2 0.47 (1.25) 97.79 5 25.29 (21.08) 1.63 0.000***
Day 4 2 0.27 (0.80) 98.73 5 28.57 (23.13) −11.12 0.000***
Day 5 1 0.20 (0.77) 99.06 5 24.86 (21.48) 3.31 0.000***
Week 1 3 0.33 (0.72) 98.45 5 29.57 (24.75) −15.01 0.000***
Week 2 7 2.00 (2.80) 90.60 5 25.43 (22.52) 1.09 0.001**
Week 3 7 5.07 (8.13) 76.16 5 29.57 (24.75) −15.01 0.001**
Week 4 8 9.33 (12.26) 56.14 5 26.29 (22.88) −2.26 0.033*
atonic seizures
Baseline frequency 7 19.20 (31.76) 5 33.14 (36.32) 0.370
Day 1 6 8.00 (13.49) 58.33 5 32.71 (33.79) 1.30 0.022*
Day 2 6 3.80 (6.11) 80.21 5 36.57 (38.32) −10.35 0.003**
Day 3 5 2.67 (3.45) 86.09 5 32.14 (33.18) 3.02 0.002**
Day 4 1 0.27 (1.03) 98.59 5 34.57 (33.07) −4.32 0.001**
Day 5 0 0.00 (0.00) 100.00 5 26.57 (24.24) 19.82 0.000***
Week 1 3 3.60 (12.08) 81.25 5 37.29 (37.84) −12.52 0.005**
Week 2 7 4.00 (7.60) 79.17 5 32.14 (33.53) 3.02 0.005**
Week 3 7 4.80 (8.25) 75.00 5 38.00 (41.03) −14.67 0.006**
Week 4 7 7.40 (9.55) 61.46 5 33.86 (38.50) −2.17 0.019*
absence seizures
Baseline frequency 9 20.47 (22.97) 4 23.14 (26.56) 0.811
Day 1 9 9.60 (12.02) 53.10 4 25.57 (28.73) −10.50 0.076
Day 2 9 5.80 (6.55) 71.67 4 25.71 (29.09) −11.11 0.018*
Day 3 4 1.33 (2.50) 93.50 4 23.00 (26.43) 0.61 0.004**
Day 4 4 0.80 (1.52) 96.09 4 23.57 (26.16) −1.86 0.002**
Day 5 2 0.53 (1.60) 97.41 4 23.86 (26.22) −3.11 0.002**
Week 1 2 1.80 (5.95) 91.21 4 21.86 (25.78) 5.53 0.008**
Week 2 7 4.27 (6.26) 79.14 4 23.86 (27.82) −3.11 0.015*
Week 3 8 5.53 (7.24) 72.98 4 23.14 (27.12) 0.00 0.026*
Week 4 8 8.60 (10.52) 57.99 4 21.00 (24.61) 9.25 0.108
Myoclonic seizures
Baseline frequency 7 15.93 (21.31) 1 7.86 (20.79) 0.414
Day 1 7 8.67 (12.97) 45.57 1 8.57 (22.68) −9.03 0.990
Day 2 7 5.67 (7.84) 64.41 1 7.14 (18.90) 9.16 0.795
Day 3 5 2.13 (3.74) 86.63 1 8.00 (21.17) −1.78 0.299
Day 4 2 0.80 (2.24) 94.98 1 9.00 (23.81) −14.50 0.189
Day 5 0 0.00 (0.00) 100.00 1 7.71 (20.41) 1.91 0.147
Week 1 3 2.53 (6.94) 84.12 1 8.86 (23.43) −12.72 0.338
Week 2 6 4.20 (6.66) 73.63 1 7.86 (20.79) 0.00 0.536
Week 3 6 5.93 (8.71) 62.77 1 7.00 (18.52) 10.94 0.854
Week 4 6 8.20 (12.07) 48.52 1 8.00 (21.17) −1.78 0.978
Partial seizures
Baseline frequency 4 3.13 (6.80) 1 3.57 (9.45) 0.902
Day 1 4 1.93 (4.38) 38.34 1 4.57 (12.09) −28.01 0.455
Day 2 4 1.00 (1.89) 68.05 1 3.86 (10.21) −8.12 0.295
Day 3 2 0.27 (0.70) 91.37 1 4.00 (10.58) −12.04 0.177
Day 4 0 0.00 (0.00) 100.00 1 3.86 (10.21) −8.12 0.147
Day 5 0 0.00 (0.00) 100.00 1 3.43 (9.07) 3.92 0.147
Week 1 0 0.00 (0.00) 100.00 1 4.00 (10.58) −12.04 0.147
Week 2 4 0.73 (1.49) 76.68 1 3.14 (8.32) 12.04 0.278
Week 3 4 0.93 (1.83) 70.29 1 3.00 (7.94) 15.97 0.339
Week 4 4 2.00 (3.55) 36.10 1 4.00 (10.58) −12.04 0.510
*p < 0.05, **p < 0.01, ***p < 0.001.
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FiGUrE 3 | Effect of tDCS on epileptiform discharges. Data are 
presented as mean ± SD of number epileptiform discharges per 30 min of 
EEG recording at baseline, and various time points after treatment: 1, 2, 3, 
and 4 weeks. **p = 0.005 and ***p < 0.001 as compared to sham tDCS 
condition.
6
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22.27 ±  16.51/day (72.39% reduction), and 35.53 ±  15.29/day 
(55.96% reduction) in 1-, 2-, 3-, and 4-week follow-up, respectively.
The numbers of individual Seizure Types
The mean numbers of baseline tonic, atonic, absence, myoclonic, 
and partial seizures in both groups are 22.68, 23.63, 21.32, 13.36, 
and 3.27, respectively. Cathodal tDCS reduced the seizure fre-
quency by more than 50% in all individual seizure types. However, 
the between group analysis reveal statistically significant decrease 
in mean seizure frequency in only tonic, atonic, and absence 
seizures (Table 2).
Epileptiform Discharges
The repeated-measures ANOVA using the epileptiform discharges 
as the dependent variable revealed significant main effects for 
group [F (1, 20) = 115.657; p < 0.001], time [F (5, 20) = 18.414; 
p <  0.001], and group ×  time interaction [F (5, 20) =  19.078; 
p < 0.001].
Post hoc analysis showed that the epileptiform discharges were 
significantly decreased in the tDCS group, relative to the sham 
tDCS group during the treatment period, at immediately post 
treatment (p < 0.001), 1 week (p < 0.001), 2 weeks (p < 0.001), 
3 weeks (p = 0.005), and 4 weeks (p = 0.090) (Figure 3).
The epileptiform discharges (EDs) counted in our study con-
sist of all spikes, sharp waves, spike waves, and slow waves. Visual 
EEG analysis, in the active tDCS group, the baseline for EDs was 
640.13 ±  263.30 events/30  min, decreased to 150.53 ±  104.80 
events/30 min (76.48% reduction) immediately after stimulation. 
After the treatment, the EDs were 235.73 ± 114.01 events/30 min 
(63.17% reduction), 367.07  ±  127.02 events/30  min (42.66% 
reduction), and 585.33 ± 127.02 events/30 min (8.56% reduction) 
in 1-, 2-, 3-, and 4-week follow-up, respectively.
Vital Signs and Oxygen Saturation
All of the patients were no clinically relevant difference between 
vital signs and oxygen saturation during the treatment and 30 min 
after the treatment period.
DiSCUSSiOn
This is the first RCT examining the efficacy of cathodal tDCS 
when combined with standard care in the treatment of patients 
with LGS. Consistent with the study hypotheses, the primary 
outcome revealed a significantly greater pre- to post-treatment 
decrease in seizure frequency that maintained for 4 weeks among 
participants in the active tDCS, relative to those in the sham tDCS 
condition. However, the statistical reductions in mean numbers 
of seizures were found in only tonic, atonic, and absence seizures. 
We also found statistically significant between-group differences 
in the secondary outcome variables emerged for epileptic dis-
charges for 3 weeks post-treatment. In addition, we also found 
significantly clinical seizure frequency reduction after the treat-
ment and extended to 4 weeks.
To the best of our knowledge, this is the first study evaluating 
cathodal tDCS in patients with LGS, a comparison with previous 
results of tDCS in this patient population is not possible. However, 
previous studies have shown the beneficial effects of cathodal 
tDCS in patients with other epilepsy conditions, especially the 
antiepileptic effect occurred immediately after stimulation (17, 
18, 24, 25). In addition, our results are consistent with our previ-
ous study, which revealed a significant epileptiform discharges 
reduction following a single cathodal tDCS over the epileptic 
focus in children with refractory focal epilepsy (18). However, 
the duration of the antiepileptic effect in this study was longer, 
e.g., epileptic discharge waves were suppressed for up to 3 weeks, 
while our previous study revealed a significant epileptiform dis-
charges reduction for 48 h after treatment. Possible explanations 
for this discrepancy are the longer duration (e.g., five consecutive 
days vs. single dose) and the higher current density (e.g., 2 vs. 
1 mA) of treatment by cathodal tDCS could be more potential 
effect on epileptic neurons.
The mechanisms of cathodal tDCS on anti-epileptic effect 
have not been clearly understood. However, the basic knowledge 
of seizure generation causes from three hallmarks, hyper-excit-
ability of neuron disinhibition and hypersynchrony of neural 
circuits (15, 26). Since cathodal tDCS induces a weak-constant 
electrical current, which increases resting membrane potential 
of neuronal cells. This action leads to decrease overall firing 
activity in the cortical areas immediately below the cathodal 
electrode (26). Therefore, it is possible that cathodal tDCS may 
inhibit the hyperexcitability of epileptic neurons. According to 
the long lasting effect of cathodal tDCS on the brain thought 
to be mediated by N-methyl-d-aspartate (NMDA) receptors 
with a long-term depression (LTD) fashion at the synaptic 
level (15). As well as the alteration in trans-membrane protein 
and changes in membrane pH could be also possible to induce 
LTD (27).
An important limitation of the current study is the standard 
procedures for electrode placement, although we used the 
international 10–20 system for tDCS electrode placement but 
we could not ensure that the stimulation electrode was directly 
over the M1. To specify the M1 site by, i.e., using transcranial 
magnetic stimulation (TMS) to locate motor responses is sug-
gested (28, 29). However, it could increase risk of the seizure 
attack in this vulnerable population. In addition, the sample 
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size of this study was small; therefore, it could have incurred 
a type II error when reporting the results for the seizure fre-
quency. Besides, the population of this study is not homogene-
ous regarding the etiology; it might also be able to bias the 
results.
In summary, to the best of our knowledge, this is the first study 
to demonstrate that cathodal tDCS over the motor cortex when 
combined with standard treatment have beneficial anti-epileptic 
effect for at least 3 weeks. Further research is needed to examine 
these effects in the potential mechanisms of treatment using 
neuroimaging techniques.
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